Catalytic mechanism of Cdc25

被引:34
|
作者
Rudolph, J [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA
关键词
D O I
10.1021/bi0263513
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cdc25 is a dual-specificity phosphatase that catalyzes the activation of the cyclin-dependent kinases, thus causing initiation and progression of successive phases of the cell cycle. Although it is not significantly homologous in sequence or structure to other dual-specificity phosphatases, Cdc25 belongs to the class of well-studied cysteine phosphatases as it contains their active site signature motif. Like other dual-specificity phosphatases, Cdc25 contains an active site cysteine whose pK(a) of 5.9 can be measured in pH-dependent kinetics using both small molecule and protein substrates such as Cdk2-pTpY/CycA. We have previously shown that the catalytic acid expected in phosphatases of this family and apparent in kinetics with the natural protein substrate does not appear to lie within the known structure of Cdc25 [Chen, W., et al. (2000) Biochemistry 39, 10781]. Here we provide experimental evidence for a novel mechanism wherein Cdc25 uses as its substrate a monoprotonated phosphate in contrast to the more typical bisanionic phosphate. Our pH-dependent studies, including one-turnover kinetics, solvent kinetic isotope effects, equilibrium perturbation, substrate depletion, and viscosity measurements, show that the monoprotonated phosphate of the protein substrate Cdk2-pTpY/CycA provides the critical proton to the leaving g I roup. Additionally, we provide evidence that Glu474 on the Cdc25 enzyme serves an important role as a base in the transfer of the proton from the phosphate to the leaving group. Because of its greater intrinsic reactivity, the use of a monoprotonated phosphate as a phosphatase substrate is a chemically attractive solution and suggests the possibility of designing inhibitors specific for the Cdc25 dual-specificity phosphatase, an important anticancer target.
引用
收藏
页码:14613 / 14623
页数:11
相关论文
共 50 条
  • [21] Dual mode of degradation of Cdc25 A phosphatase
    Donzelli, M
    Squatrito, M
    Ganoth, D
    Hershko, A
    Pagano, M
    Draetta, GF
    EMBO JOURNAL, 2002, 21 (18): : 4875 - 4884
  • [22] Cdc25 protein phosphatases in cell proliferation
    Draetta, G.
    Eckstein, J.
    B B A - Biomembranes, 1332 (02):
  • [23] CDC25 PHOSPHATASES AS POTENTIAL HUMAN ONCOGENES
    GALAKTIONOV, K
    LEE, AK
    ECKSTEIN, J
    DRAETTA, G
    MECKLER, J
    LODA, M
    BEACH, D
    SCIENCE, 1995, 269 (5230) : 1575 - 1577
  • [24] Cdc25 as a Potential Target of Anticancer Agents
    Jens W. Eckstein
    Investigational New Drugs, 2000, 18 : 149 - 156
  • [25] Cell Cycle Control by the CDC25 Phosphatases
    Aressy, Bernadette
    Ducommun, Bernard
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2008, 8 (08) : 818 - 824
  • [26] Cdc25 protein phosphatases in cell proliferation
    Draetta, G
    Eckstein, J
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1997, 1332 (02): : M53 - M63
  • [27] Design of covalent inhibitors of Cdc25 phosphatases
    Muus, Ulrike
    Lountos, George T.
    Waugh, David S.
    Burke, Terrence R., Jr.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 238
  • [28] Cdc25: mechanisms of checkpoint inhibition and recovery
    Karisson-Rosenthal, Christina
    Millar, Jonathan B. A.
    TRENDS IN CELL BIOLOGY, 2006, 16 (06) : 285 - 292
  • [29] Flexibility and inhibitor binding in Cdc25 phosphatases
    Arantes, Guilherme Menegon
    PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2010, 78 (14) : 3017 - 3032
  • [30] Targeting CDC25 phosphatases in cancer therapy
    Ducommun, B.
    Prevost, G.
    Cazales, M.
    Brezak, M.
    Boutros, R.
    Contour-Galcera, M.
    Chaumeron, S.
    Quaranta, M.
    EJC SUPPLEMENTS, 2006, 4 (12): : 89 - 89